导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -18.83% | 4298/4773 |
| 近一周 | -4.92% | 5165/5462 |
| 近一月 | -2.88% | 1448/5421 |
| 近一季 | -9.77% | 3332/5209 |
| 近半年 | -24.88% | 4705/4920 |
| 近一年 | -18.28% | 3860/4366 |
| 近两年 | 10.42% | 2805/2954 |
| 近三年 | -28.64% | 2200/2253 |
| 成立以来 | 3.72% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.93% 1409/4961 |
-14.31% 4566/5312 |
- - |
- - |
| 2025 | 7.46% 2925/4813 |
0.55% 1820/3635 |
-3.16% 3415/4076 |
8.16% 3416/4524 |
2.03% 1105/4813 |
| 2024 | -4.03% 2228/3463 |
-6.23% 2029/2808 |
-6.55% 1975/3014 |
13.40% 2172/3129 |
-3.42% 2341/3463 |
| 2023 | -20.98% 1890/2656 |
1.42% 1575/2280 |
-11.23% 2154/2385 |
2.13% 253/2515 |
-14.05% 2476/2655 |
| 2022 | -22.70% 1082/2207 |
-7.14% 236/1919 |
2.89% 1241/2016 |
-21.57% 1906/2113 |
3.15% 759/2208 |
| 2021 | 10.47% 432/1822 |
8.74% 59/1255 |
-0.80% 1151/1330 |
-2.57% 581/1466 |
5.10% 304/1822 |
| 2020 | 22.70% 667/1250 |
-0.44% 186/1028 |
5.33% 885/1067 |
16.12% 167/1164 |
0.77% 1050/1184 |
| 2019 | 52.07% 92/1092 |
33.17% 140/739 |
-0.69% 274/788 |
-4.53% 775/850 |
20.44% 4/918 |
| 2018 | -26.15% 373/834 |
- - |
-18.06% 595/631 |
1.09% 142/660 |
-11.66% 336/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 广发中证全指建筑材料指数A VS. 长安沪深300非周期A(740101) |